PharmacyTech News - Winter 2009 - The Cyberspace Race (Page 7)

#1 dispensed OC1*

Models used for illustrative purposes only.

Bayer

Yaz

BIRTH CONTROL – IT’S JUST ONE PART OF HER LIFE

;;;;CONTRACEPTIVE;EFFICACY;WHEN;TAKEN;AS;DIRECTED

4REATMENT;OF;THE;EMOTIONAL;AND;PHYSICAL;SYMPTOMS;OF;PREMENSTRUAL;DYSPHORIC;DISORDER;;0-$$ s The effectiveness of YAZ® for PMDD when used for more than 3 menstrual cycles has not been evaluated. YAZ has not been evaluated for the treatment of premenstrual syndrome (PMS) 4REATMENT;OF;MODERATE;ACNE s For women at least 14 years of age, who have no known contraindications to oral contraceptive therapy and have achieved menarche

Important Safety Information About YAZ s; 9!:;;DROSPIRENONE;;;ETHINYL;ESTRADIOL;;CONTAINS;;;MG;OF;THE;PROGESTIN;DROSPIRENONE;THAT;HAS;!NTI-INERALOCORTICOID;ACTIVITY;INCLUDING;THE;POTENTIAL;FOR;HYPERKALEMIA;IN;HIGH;RISK;PATIENTS COMPARABLE;TO;A;;;;MG;DOSE;OF;SPIRONOLAC TONE; 9!:;SHOULD;NOT;BE;USED;IN;PATIEN TS; WITH;CONDI TIONS; THAT;PREDISPOSE; TO;H YPERKALEMIA;;IE ;RENAL;INSUFlCIENC Y ;HEPATIC;D YSFUNCTION ;AND ADRENAL;INSUFlCIENCY;; 7OMEN;RECEIVING;DAILY;;LONG;TERM; TREA TMEN T;FOR;CHRONIC;CONDI TIONS;OR;DISEASES;WITH;MEDICA TIONS; THA T;MAY;INCREASE;SERUM;POTASSIUM;SHOULD;HAVE; THEIR;SERUM POTASSIUM;LEVELS;CHECKED;DURING;THE;lRST;TREATMENT;CYCLE;;-EDICATIONS;THAT;MAY;INCREASE;SERUM;POTASSIUM;INCLUDE;!#%;INHIBITORS;;ANGIOTENSIN;));RECEPTOR;ANTAGONISTS;;POTASSIUM;SPARING DIURETICS;;POTASSIUM;SUPPLEMENTA TION;;HEPARIN;;ALDOSTERONE;ANTAGONISTS;;AND;. 3!)$S; s;0ATIENTS;SHOULD;BE;COUNSELED;THAT;/#S;DO;NOT;PROTECT;AGAINST;() 6;INFECTION;AND;OTHER;SEXUALLY;TRANSMITTED;DISEASES; s The use of oral contraceptives is associated with increased risks of several serious conditions including venous and arterial thrombotic and thromboembolic events (such as myocardial infarction, thromboembolism, stroke), hepatic neoplasia, gallbladder disease, and hypertension. #IGARE TTE;SMOKING;INCREASES; THE;RISK;OF;SERIOUS;CARDIOVASCULAR;SIDE;EFFECTS;FROM;/#;USE; 7OMEN; WHO TAKE;/#S;;ESPECIALLY; THOSE;;;;AND;OVER;;ARE;STRONGL Y;ADVISED;NOT; TO;SMOKE;BECAUSE;I T;INCREASES;THESE;RISKS; OCs should not be used in women with a high risk of arterial or venous thrombotic diseases, certain cancers (such as breast or liver cancer), a history of myocardial infarction or stroke, or who are pregnant.

For women who choose an OC for contraception, YAZ is the only OC with 3 indications

Adverse Reactions s;4HE;MOST;FREQUEN T;;;;;;; TREA TMEN T;EMERGEN T;ADVERSE;EVEN TS;; WHICH;MAY;OR;MAY;NO T;BE;DRUG;RELATED;;COMMON; TO;ALL; THREE; TYPES;OF;CLINICAL; TRIALS;INCLUDED;;upper respiratory infection, headache, breast pain, vaginal moniliasis, nausea, abdominal pain, dysmenorrhea, urinary tract infection, accidental injury, sinusitis, emotional lability, suspicious Papanicolaou smear, weight gain, depression, menstrual disorder, and asthenia. s;4HE;FOLLOWING;ADVERSE;EVENTS;;;;;;;WHICH;MAY;OR;MAY;NOT;BE;DRUG;RELATED;;WERE;EITHER;UNIQUE;TO;EACH;TRIAL;TYPE;OR;OCCURRED;IN;ONLY;TWO;TYPES;OF;CLINICAL;TRIALS;

s;)N;THE;CON TRACEP TION; TRIAL; leukorrhea, diarrhea, vomiting, vaginitis, flu syndrome, moniliasis, allergic reaction, cystitis, tooth disorder, sore throat, infection, fever, surgery, back pain, migraine, dyspepsia, rhinitis, acne, gastroenteritis, bronchitis, pharyngitis, skin disorder, intermenstrual bleeding, decreased libido, pain, increased cough, dizziness, pain in extremity, and pelvic pain. s;)N; THE;0-$$; TRIALS; intermenstrual bleeding, decreased libido, nervousness, menorrhagia, pain in extremity, migraine, vaginitis, hyperlipidemia, back pain, diarrhea, increased appetite, enlarged abdomen, and acne. s;)N;THE;ACNE;TRIALS; metrorrhagia, flu syndrome, menorrhagia, gastroenteritis, tooth disorder, infection, vomiting, pharyngitis, sore throat, arthralgia, bronchitis, rhinitis, amenorrhea, and urine abnormality.

Please see next page for a brief summary of Prescribing Information. Visit www.YAZ-us.com for more information. *According to data from Wolters Kluwer Health, Source® Pharmaceutical Audit Suite (PHAST). Based on review and analysis of US retail pharmacy claims processed for the 12 months ending April 2009.1 Reference: 1. Data on file. Wolters Kluwer Health, Source® Pharmaceutical Audit Suite (PHAS T). Bayer HealthCare Pharmaceuticals Inc.

BAYER, the Bayer Cross, and YAZ are registered trademarks of Bayer. Beyond Birth Control is a trademark of Bayer.